Abbreviations used: ET, endothelin; Mc-cpa, mast cell carboxypeptidase A; Mcp, mast cell protease; PEC, peritoneal exudate cell; S6b, sarafotoxin 6b. L.A. Schneider, S.M. Schlenner, and T.B. Feyerabend contributed equally to this paper. Mast cells are protective against snake venom sarafotoxins that belong to the endothelin (ET) peptide family. The molecular mechanism underlying this recently recognized innate defense pathway is unknown, but secretory granule proteases have been invoked. To specifi cally disrupt a single protease function without affecting expression of other proteases, we have generated a mouse mutant selectively lacking mast cell carboxypeptidase A (Mc-cpa) activity. Using this mutant, we have now identifi ed Mc-cpa as the essential protective mast cell enzyme. Mass spectrometry of peptide substrates after cleavage by normal or mutant mast cells showed that removal of a single amino acid, the C-terminal tryptophan, from ET and sarafotoxin by Mc-cpa is the principle molecular mechanism underlying this very rapid mast cell response. Mast cell proteases can also cleave ET and sarafotoxin internally, but such " nicking " is not protective because intramolecular disulfi de bridges maintain peptide function. We conclude that mast cells attack ET and sarafotoxin exactly at the structure required for toxicity, and hence sarafotoxins could not " evade " Mc-cpa ' s substrate specifi city without loss of toxicity.
Mast cells have crucial functions in innate immunity. A protective role of mast cells is evident in mast cell -defi cient mice that are unprotected from acute bacterial peritoneal infection and subsequent sepsis ( 1, 2 ) . Although this protection has largely been attributed to rapid release of mast cell -derived TNF, other mechanisms also contribute. A molecule of critical importance in the pathology of sepsis is endothelin-1 (ET-1; for reviews see references 3 -5 ) . ET-1 is a highly potent blood pressure -regulating peptide. Under physiological conditions, ET-1 is produced primarily by endothelial cells, and it is mostly secreted toward the abluminal side of the vessel wall, where it regulates the blood pressure via contraction of smooth muscle cells (for review see reference 6 ) ( 7 ). Cell types other than endothelium, notably monocytes and tissue macrophages ( 8 ) , cardiomyocytes, tracheal epithelium, and kidney and liver cells, are additional sources of ET-1 (for review see reference 4 ). During sepsis, ET-1 production is rapidly stimulated by infl ammatory mediators, including TNF, IL1 ␤ , and TGF ß ( 4, 9 ) . A link between mast cells and ET has been found. Mast cells express ET receptors, and binding of ET-1 to mast cells induces potent degranulation and release of mast cell granule content ( 10, 11 ) . This release protects normal mice, but not mast cell -defi cient mice, from the lethal eff ects of intraperitoneal injection of ET-1, possibly connecting the mast cell -dependent survival of peritoneal sepsis with ET-1 ( 11 ) . Direct activation of mast cells by ET-1 is important in this process because ET receptor (ET A ) expression on mast cells contributes to protection ( 11 ) . Because large amounts of ET-1 were applied in these studies, the physiological or pathological relevance for the " mast cell -ET link " is less clear. However, mast cells are also essential for survival of mice challenged with snake venom sarafotoxin 6b (S6b) ( 12 ) , which is a peptide homologous to ET-1. The function of mast cells in antitoxin protection is thus a novel aspect of innate immunity.
Peritoneal mast cells produce a multitude of granule proteases, which include one carboxypeptidase (mast cell carboxypeptidase A [Mc-cpa; also termed Cpa3]), chymases (mast cell protease 4 and , and tryptases (Mcp-6 and -7; for reviews see references 13 -15 ) . Although these enzymes were identifi ed many years ago, and studied extensively in vitro, information about their in vivo functions is scarce. A major hurdle to uncover the functions of Mcps has been the diffi culty to identify relevant in vivo substrates. This problem can now be addressed in mutant mice for Mc-cpa ( 16 ) , , and genes. Resistance of Mcp-4 Ϫ / Ϫ mice to ET-1/S6b excludes an essential protective function of this enzyme ( 12 ) . Mc-cpa ( 19 ) , which is a mast cell -specifi c enzyme related to pancreatic carboxypeptidases, preferentially cleaves C-terminal aromatic amino acids. Mc-cpa is the only mast cell enzyme with carboxypeptidase activity, but mast cells lacking Mc-cpa develop in normal numbers, and are fully competent in degranulation, histamine release, and passive cutaneous anaphylaxis ( 16 ) .
Mcps are assembled in conjunction with proteoglycans during their synthesis in the secretory pathway (for review see reference 20 ) . -4) ( Fig. 1 C ) ( Fig. 1 B ) . Mc-cpa Ϫ / Ϫ mast cells are also devoid of Mcp-5 protein ( Fig. 1 A , lane 7 Mast cells express ET-1 receptors on their surface, and binding of ET-1 to ET-1 receptors is a potent stimulus for release of secretory granules ( 10, 11 ) . Using RT-PCR, we compared the expression of two ET-1 receptors, the ET A and ET B , in purifi ed peritoneal mast cells. ET A is the receptor type that is predominantly, if not exclusively, expressed on peritoneal mast processes, including shock and sepsis (for reviews see references 6, 7 ). In an in vivo model of the pathological eff ects of ET-1, intraperitoneal injection of 3 g ET-1 per mouse caused a rapid drop in body temperature and the death of two thirds of Kit W/Wv , but not wild-type, mice ( 11 ) . In our hands, injection of 7.5 g ET-1 into mast cell -positive Kit ϩ/ϩ mice (designated as Mc-cpa ϩ/ϩ mice in Fig. 2 A ) showed a transient temperature drop, and 14/15 mice fully recovered ( Fig. 2 A ) . In contrast, the same dose caused a massive temperature drop within 20 min, and the death of 9/9 Kit W/Wv mice by 60 min ( Fig. 2 B ) . Hence, this dose was used for all subsequent experiments.
To analyze whether Mc-cpa and/or Mcp-5 are involved in protection against ET-1, Mc-cpa Ϫ / Ϫ mice were challenged by ET-1 ( Fig. 2 C ) . Similar to mast cell -defi cient mice ( Fig. 2 B Fig. 1 A ) . Mc-cpa ϩ/ Ϫ mice were protected, which implies that a reduction in protease expression does not impair the defense against the applied dose of ET-1 ( Fig. 2 D ) . Interestingly, Mc-cpa Y356L,E378A mice were largely susceptible to ET-1 ( Fig.  2 E ) . However, when compared with Mc-cpa Ϫ / Ϫ mice ( Fig. 2 C ) , the kinetic of the temperature drop was delayed, i.e., 8/21 mice survived beyond 60 min, and another 2/21 survived indefi nitely. Nevertheless, Mc-cpa Y356L,E378A mice were clearly susceptible to ET-1, which demonstrates a nonredundant role for Mc-cpa, but not Mcp-5, in resistance to ET-1.
Mast cell -mediated degradation of ET-1
To address a mechanistic link between mast cells and survival of the mice in response to exogenously applied ET-1, one H 2 O = 2,510 daltons), which pointed at hydrolysis of one peptide bond within the ET-1 molecule. ET-1 harbors two intramolecular disulfi de bridges linking the cysteine in position 1 with that in position 15, and the cysteines in positions 3 and 11 ( 27 ) . In the absence of C-terminal degradation, the overall maintained length of the peptide could mask internal cleavage of ET-1 between the disulfi de bridges by a mast cell -derived endopeptidase. To address this possibility, ET-1 was incubated with Mc-cpa Y356L,E378A mast cells, and half of the supernatant was kept under nonreducing conditions in which ET-1 remained full length ( Fig. 3 E ) . The second half was reduced to open the disulfi de bridges. Under reducing conditions, ET-1 ( 1 -21 ) disappeared, and shorter peptide fragments became apparent ( Fig. 3 F ) , which is consistent with an ET-1 cleavage at positions 13 and 14, i.e., within the two cysteines in positions 11 and 15. Thus, mast cell products attack ET-1 internally, causing a nick in the peptide that could only be revealed under reducing conditions. This internal nicking was not mediated by Mcp-5 because the same pattern of degradation products was generated by Mc-cpa Ϫ / Ϫ mast cells lacking both Mc-cpa and Mcp-5.
These data strongly suggested that the Mc-cpa -catalyzed removal of a single amino acid (tryptophan) from the C terminus of ET-1 was necessary and suffi cient for the mast cellmediated inactivation of ET-1. To prove that C-terminal de gradation of ET-1 was suffi cient for protection, synthetic peptides corresponding to full-length ET-1 (1-21) or Cterminally shorter peptides were injected into mast cell -deficient Kit W/Wv mice ( Fig. 4 ) . Of these, only full-length ET-1 ( Fig. 4 A ) , but neither the 1 -20 ( Fig. 4 B ) , nor the 1 -19 peritoneal mast cells were incubated with ET-1 in vitro. Initially, we measured ET-1 degradation by an ET-1 -specifi c ELISA. This assay has previously been reported to measure mast cell -mediated degradation of ET-1, and to reveal the mechanism behind how mast cells limit ET-1 toxicity ( 11 ). ET-1 was incubated for 60 min with PECs from Mc-cpa ϩ/ϩ , Mc-cpa Ϫ / Ϫ , or Kit W/Wv mice ( Fig. 3 A ) . ( Fig. 2 A ) , whereas Mc-cpa Ϫ / Ϫ mice were fully susceptible ( Fig. 2 C ) to ET-1. This discrepancy implied that the loss of ELISAreactivity did not indicate whether or not ET-1 remained biologically active.
It was, therefore, of interest to obtain more direct data on mast cell -mediated ET-1 degradation to correlate specifi c degradation products with survival. To this end, ET-1 was incubated with mast cells of diff erent genotypes, and the products were analyzed by mass spectrometry ( Fig. 3, B-F 
mice were incubated in the presence of ET-1 together with ionomycin for maximal stimulation. The resulting ET-1 fragments were measured by mass spectrometry. Synthetic peptides corresponding to ET-1 (1 -21; Fig. 3 B ) , or peptides lacking one (1 -20) or two (1 -19) amino acids at the C terminus (not depicted) were measured separately, as standards.
In the presence of Mc-cpa ϩ/ϩ mast cells, most ET-1 (1 -21) was converted into shorter fragments with masses of 1 -20 and 1 -19 ( Fig. 3 C ) . C-terminal degradation products were not generated by Mc-cpa Ϫ / Ϫ mast cells ( Fig. 3 D ) . Thus, mast cells can degrade ET-1 at the C terminus, and this degradation requires expression of Mc-cpa or Mcp-5. To directly analyze the role of Mc-cpa in this process, ET-1 was incubated with Mc-cpa Y356L,E378A mast cells ( Fig. 3 E ) . Interestingly, ET-1 (1 -21) was also maintained in the presence of these mutant mast cells lacking only catalytically active Mc-cpa. These experiments unequivocally identify Mc-cpa as the nonredundant enzyme required for removal of C-terminal amino acids from ET-1.
ET-1 can also be cleaved at multiple positions by endopeptidases ( 27 ) . Along this line, Mcps other than Mc-cpa, notably chymases ( 11, 28 ) , were reported to contribute to ET-1 degradation, and cleavage by chymases has, in fact, been proposed as the protective mechanism ( 11 ) (for review see reference 29 ). Mast cells from Mc-cpa Ϫ / Ϫ and Mc-cpa Y356L,E378A mice could not degrade the C terminus of ET-1, but we noticed a shift in the molecular mass of ET-1 from 2,492 (ET-1) to 2,510 daltons ( Fig. 3, D and E ) . This increase in molecular weight suggested addition of a water molecule (ET-1 plus (not depicted) amino acid long peptides induced a temperature drop or lethality in Kit W/Wv mice.
Collectively, Mc-cpa ϩ/ϩ , but not Mc-cpa Y356L,E378A , mast cells degrade the C terminus of ET-1, and this Mc-cpamediated C-terminal shortening is highly protective because ET-1 (1-20) was not toxic in vivo ( Fig. 4 B ) . Moreover, Mcps other than Mc-cpa and Mcp-5 can nick internal peptide bonds between cysteines 11 and 15 in ET-1. Apparently, the ELISA detects a conformation-dependent epitope that is missing in nicked ET-1. In contrast, in vivo experiments demonstrated that such heterodimers of internally cleaved, but " full-length " ET-1 remained lethal in Mc-cpa Ϫ / Ϫ and Mc-cpa Y356L,E378A mice ( Fig. 2 ) .
Catalytic activity of Mc-cpa is essential to protect against snake venom sarafotoxin Snake venom sarafotoxins share signifi cant amino acid sequence similarity with endogenous ET-1 ( 27, 30 ) . This sequence homology appears to be immunologically relevant because mast cells can enhance resistance not only to ET-1 but also to snake venom sarafotoxins ( 12 ) . The molecular mechanism under lying the mast cell -mediated degradation of sarafotoxins has not been fully uncovered. Given the similarities in sequence and structure involving two disulfi de bridges, it appears likely that the mechanisms of ET and sarafotoxin degradation are similar, if not identical. However, the specifi c role of Mc-cpa could not easily be addressed up to now because ablation of ( Fig. 5 ) . Mc-cpa ϩ/ϩ and Mc-cpa ϩ/ Ϫ mice were protected ( Fig. 5 A ) , but mast cell -defi cient Kit W/Wv mice were not ( Fig.  5 B ) , thereby confi rming a crucial role of mast cells in the protection against S6b in vivo ( 12 ( Fig. 5 C ) . Interestingly, Mc-cpa Y356L,E378A mice were also fully susceptible to S6b ( Fig. 5 D ) . In contrast to the delayed ET-1 -induced lethality of Mc-cpa Y356L,E378A mice when compared with Kit W/Wv or to Mc-cpa − / − mice ( Fig. 2 ) ( Fig. 5 ) . These experiments establish an essential role for Mc-cpa in the mast cell defense against S6b.
Mast cell -mediated, C-terminal degradation of S6b
S6b degradation products that were generated by incubation of S6b with ionomycin-stimulated peritoneal mast cells from Mc-cpa ϩ/ϩ , Mc-cpa Ϫ / Ϫ , or Mc-cpa Y356L,E378A mice were analyzed by mass spectrometry ( Fig. 6 ) . We observed C-terminal shortening C terminus. Hence, Mc-cpa activity is not only essential for C-terminal degradation of ET-1 but also of S6b.
The sequences of ET-1 and S6b are identical in 14/21 amino acids, and S6b, like ET-1, contains two disulfi de bridges.
of S6b ( Fig. 6 A ) by Mc-cpa ϩ/ϩ mast cells ( Fig. 6 B ) . Consistent with the susceptibility of Mc-cpa Ϫ / Ϫ and Mc-cpa Y356L,E378A mice to S6b ( Fig. 5 ) ( Fig. 6 C ) mice failed to degrade S6b at the The homology is even higher between positions 8 and 21 (identity in 11/14 amino acids). In ET-1, the degradation products were consistent with endopeptidase cleavage at position 13 or 14. Tyrosine ( 13 ) and phenylalanine ( 14 ) are conserved in ET-1 and S6b. To determine whether mast cell products also cleaved S6b internally, S6b was incubated with Mc-cpa Y356L,E378A mast cells, and the samples were analyzed with and without reduction by mass spectrometry. Without reduction, addition of a water molecule, which is indicative of hydrolysis of as single-peptide bond, was revealed by the corresponding mass increase ( Fig. 6 C ) . After reduction, S6b ( 1 -21 ) disappeared, and reaction products consistent with the masses of 1 -13 and 1 -14 fragments of S6b ( Fig. 6 D ) pointed at an identical endopeptidase digestion pattern comparing ET-1 and S6b. The identical pattern of reduced S6b reaction products occurred when Mc-cpa Ϫ / Ϫ mast cells were incubated with S6b (not depicted). Thus, as for ET-1, the internal cleavage was not mediated by Mcp-5, and internally nicked, C-terminally intact S6b remained lethal.
DISCUSSION
In contrast to the notoriously harmful role of mast cells in allergic disease, new mast cell functions in immunity are emerging. Mast cell properties such as protection against the lethal toxicity of snake venom sarafotoxins raise questions as to which mast cell eff ector molecules mediate these innate immune responses, and by what mechanism. Mcps are good candidates for relevant eff ector molecules because they represent major protein components in mast cell granules that are secreted during signaling-dependent degranulation. However, Mcps have been commonly viewed as tissue damaging ( 31 ) . In contrast, the high degree of evolutionary conservation of Mcps in various species, as well as the strong expression of proteases, suggests positive functions. Impaired worm expulsion in mice lacking a mucosal Mcp, Mcp-1 ( 32 ) , is an example of a protease contributing to protection.
Recent reports demonstrated that mast cells must be present in the peritoneal cavity for mice to survive a challenge with the blood pressure regulating peptide ET-1 ( 11 ) , and the related S6b ( 12 ) . Protection against these peptides is initiated by binding of ET or sarafotoxin to ET receptors that induce rapid and potent degranulation of peritoneal mast cells ( Fig. 7 , A-C ) ( 10, 11 ) . ET A is the major ET receptor expressed on peritoneal mast cells (not depicted) ( 11 ) , and expression of ET A on mast cells is important, as ET A -defi cient mast cells are nonprotective ( 11 ) .
Attempts have been made to identify the relevant eff ector molecules. Because mast cell stimulation by ET-1 causes degranulation, but also the production of cytokines such as TNF-␣ and IL-6 ( 10 ), a large number of well-known factors could be considered. Because ET-1 and S6b are peptides, the underlying mechanism could be Mcp-mediated proteolysis that abrogates the lethal action of ET-1 and S6b in vivo ( 33 ) . Earlier in vitro experiments showed that mast cell enzymes can degrade ET-1 ( 28 ). Maurer et al. ( 11 ) used pharmacological protease-inhibitors to characterize the ET-1 -degrading in vivo toxicity. It remains to be determined whether internal cleavage has absolutely no eff ect on the biological activity of ET-1 in vivo.
The in vivo toxicity of mast cell -mediated degradation products of ET-1 is in agreement with previous structurefunction analyses of ETs. ETs nicked by endopeptidase maintains toxicity ( 27 ) , whereas the two C-terminal residues (Ile and Trp) are important for receptor binding and biological activity of ETs ( 34, 35 ) . A note of caution should be made regarding ELISA measurements of ET-1 degradation. This assay, used before to correlate in vitro degradation with in vivo toxicity ( 11 ) , was, in our hands, misleading because it indicated degradation even by mast cells that could not protect mice in vivo ( Fig. 2 versus Fig. 3 ). It is possible that immunoreactivity in this assay was abrogated by the internal nicks, or by conformational changes. In any case, it may be prudent to consider the biological activity of ET-1 when further studying the mast cell -mediated degradation of ET-1 in the future.
Collectively, we have shown that Mc-cpa is an essential eff ector molecule within the " mast cell -ET link " providing a very rapid (minutes) and life-saving response of toxin neutralization in vivo. Several sites on ET-1 are attacked by mast cells but only the C-terminal degradation is a safeguard. It is remarkable that the protective Mcp, Mc-cpa, " targets " exactly that amino acid in snake venom sarafotoxin that is essential for toxicity. This substrate specifi city of Mc-cpa, as well as the fast circuit composed of binding of sarafotoxin to ET receptors, expressed on the cell surface of mast cells, followed by the rapid degranulation, release of the protective enzyme, and cleavage of the toxin, may represent an evolutionarily well conserved, and hence old, function of mast cells. ET-1 levels in plasma, liver, and peritoneal cavity rapidly rise during experimental sepsis, such as in cecal ligation and puncture models ( 36 -38 ) . Moreover, in human sepsis patients, high levels of ET-1 are correlated with morbidity and mortality ( 4, 39 ) . ET-1 is thought to be involved in the pathological manifestations of sepsis in many organs, including heart, lung, liver, kidney, and intestines ( 4, 9 ) . Massive local or systemic ET-1 -mediated vasoconstriction ( 40 ) is a major pathological mechanism in sepsis as shown by benefi cial eff ects of ET receptor antagonist treatment in models of sepsis ( 41 ) . The observation that mast cells are closely located, among other sites, to blood vessels, and present in the peritoneal cavity, suggests that mast cells are exposed systemically or locally to changes in ET-1 levels ( 42 ). Mast cells are not only activated by ET-1 via ET A ( 10 ) but also have a potent mechanism to inactivate ET-1 via secretion of Mc-cpa. Hence, mast cells may play an important role in either promoting an infl ammatory cascade in response to ET A stimulation by releasing mediators such as TNF or in dampening the deleterious pathophysiological eff ects of ET-1 on the vascular system by Mc-cpa -mediated rapid cleavage of ET-1. It remains to be determined under which conditions of local or systemic infl ammation the eff ect of ET-1 on mast cells and the reciprocal inactivation of ET-1 by mast cells prevail.
Mcp, and concluded that a mast cell chymase, but not Mc-cpa, was responsible for ET-1 inactivation in the peritoneal cavity ( 29 ) . In contrast to these pharmacological blocking studies, a role for Mc-cpa in ET-1 and also S6b degradation in vivo was suggested in more recent experiments by the same group using RNA interference (RNAi) ( 12 ) . It must be pointed out that the latter experiment led to a reduction of Mc-cpa expression in mast cells to ‫ف‬ 20% of the wildtype level, but also, as expected from our previous knockout experiments ( 16 ) Y356L ,E378A mice by ET-1 and S6b now revealed directly that the enzyme activity of Mc-cpa is essential for protection against ET-1 ( Fig. 2 ) and S6b ( Fig. 5 ) . Identifi cation of Mc-cpa as the functionally relevant enzyme also helped to clarify which proteolytic mechanism is protective. Combining the genetic defects of Mc-cpa Ϫ / Ϫ or Mc-cpa Y356L,E378A mast cells with mass spectrometric analyses of substrates showed two sites of attack. The fi rst is C-terminal removal of one ( Fig.  7 D ) or two ( Fig. 7 F ) , or more ( 28 ) amino acids. This step is exclusively catalyzed by Mc-cpa as shown by intact C termini after contact with Mc-cpa Y356L,E378A mast cells ( Fig. 7 I ) . That this is the protective reaction was further supported by the lack of toxicity of synthetic ET-1 (1 -20) in mast cell -defi cient mice ( Fig. 4 ) . The second site of attack is internal cleavage at positions 13 or 14 (Fig. 7 E) . This could be conclusively detected in the absence of C-terminal degradation, i.e., in the presence of mutant mast cells lacking Mc-cpa protein ( Mc-cpa Ϫ / Ϫ ; not depicted) or activity ( Mc-cpa Y356L,E378A ; Figs. 3 F and 6 D ) under reducing conditions. Because hydrolysis was seen using Mc-cpa Ϫ / Ϫ mast cells ( Fig. 3 D ) , the reaction is not catalyzed by Mcp-5. The consequence of internal attack on ET-1 by mast cells remains elusive because only C-terminal degradation correlated with abrogation of were excluded from the analysis. Changes in body temperature were followed by periodic measurements of rectal temperature using a Qtemp 200 (VWR International) thermometer.
Mass spectrometry. 15,000 PMCs (Kit + PEC) in 120 l acetate buff er (150 mM NH 4 Ac, pH 7.4, 130 mM NaCl, and 1.4 mM CaCl 2 ) were prewarmed for 10 min at 37 ° C, and stimulated by the addition of 2 M ionomycin and 1.25 g ET-1, or by the addition of 2 M ionomycin and 1.25 g S6b. After incubation at 37 ° C for 60 min, the cells were pelleted at 500 g for 3 min and 100 l of supernatant was split into 2 50-l aliquots. For reducing conditions, the sample was dried again under vacuum, resuspended in 10 l DTT solution (2.5 mM DTT in 10 mM NH 4 HCO 3 ), and incubated overnight at 4 ° C. After addition of 2.5 l IAA solution (10 mM IAA in 10 mM NH 4 HCO 3 ), the sample was incubated for 30 min in the dark. Under reducing conditions, the molecular mass of the fragments was increased by the binding of one IAA molecule (molecular weight, 58 daltons) to each sulfate group. Nonreduced and reduced samples were desalted with PerfectPure C18 tips (Eppendorf), eluted with 10 l acetonitril/0.1% TFA, and mixed 1:1 with ␣ -cyano-4-hydroxycinnaminic acid matrix before analysis. Mass spectrometry was done on a REFLEX IV MALDI-TOF mass spectrometer (Bruker-Daltonics). Full-length ET-1 was purchased by Sigma-Aldrich or custom made by Bachem (ET-1 in the length of 1 -19, 1 -20, and 1 -21), and S6b was purchased from Alexis.
ET ELISA. To measure the potential degradation of ET-1 by ELISA, mast cell -containing PECs were resuspended in 120 l Tyrode ' s buff er (see Mast cell degranulation assay), and incubated with 1.25 g ET-1 for 30 min at 37 ° C to stimulate degranulation, as shown in Fig. 1 C . At the end of the incubation period that allowed mast cell products to " attack " ET-1, cells were pelleted at 500 g for 3 min at 4 ° C, and supernatants were collected. Samples of these supernatants were tested in the ␤ -hexosaminidase assay to control for degranulation, and analyzed by ELISA for residual ET-1. The ELISA kit (Biomedica) was used according to the manufacturer ' s instructions. Serial dilutions of the samples were analyzed in parallel. The amount of input versus output ET-1 was taken as a measure for mast cell -mediated ET-1 degradation. Data were analyzed by Student ' s t test.
